CY1123743T1 - Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου - Google Patents

Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου

Info

Publication number
CY1123743T1
CY1123743T1 CY20201101196T CY201101196T CY1123743T1 CY 1123743 T1 CY1123743 T1 CY 1123743T1 CY 20201101196 T CY20201101196 T CY 20201101196T CY 201101196 T CY201101196 T CY 201101196T CY 1123743 T1 CY1123743 T1 CY 1123743T1
Authority
CY
Cyprus
Prior art keywords
antibody
igf
cancer treatment
targeting vehicle
binding
Prior art date
Application number
CY20201101196T
Other languages
English (en)
Inventor
Liliane Goetsch
Matthieu BROUSSAS
Charlotte Beau-Larvor
Thierry Champion
Alain Robert
Original Assignee
Pierre Fabre Médicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Médicament filed Critical Pierre Fabre Médicament
Publication of CY1123743T1 publication Critical patent/CY1123743T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ένα αντίσωμα, ειδικότερα ένα μονοκλωνικό αντίσωμα, δυνάμενο δέσμευσης σε IGF-1R, ως επίσης και με τις αλληλουχίες αμινοξέων και πυρηνικών οξέων κωδικεύοντας το εν λόγω αντίσωμα. Από μία άποψη του θέματος, η εφεύρεση που σχετίζεται με ένα αντίσωμα, ή ένα θραύσμα αντιγόνου εξ αυτού, δυνάμενο δέσμευσης σε IGF-1R και, από επαγωγή εσωτερικοποίησης του IGF-1R, εσωτερικοποιείται μέσα στο κύτταρο. Η εφεύρεση περιλαμβάνει επίσης τη χρήση του εν λόγω αντισώματος ως ένα προϊόν ή ουσία-όχημα διευθυνσιοδότησης σε σύζευξη με άλλες ενώσεις κατά των καρκίνων όπως είναι οι τοξίνες, τα ραδιο-στοιχεία ή φάρμακα, και τη χρήση των ιδίων για την αγωγή ορισμένων καρκίνων.
CY20201101196T 2014-04-25 2020-12-18 Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου CY1123743T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984160P 2014-04-25 2014-04-25
PCT/EP2015/059050 WO2015162292A1 (en) 2014-04-25 2015-04-27 Igf-1r antibody and its use as addressing vehicle for the treatment of cancer

Publications (1)

Publication Number Publication Date
CY1123743T1 true CY1123743T1 (el) 2022-03-24

Family

ID=53373391

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101196T CY1123743T1 (el) 2014-04-25 2020-12-18 Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου

Country Status (29)

Country Link
US (2) US10202458B2 (el)
EP (2) EP3134438B1 (el)
JP (2) JP6835591B2 (el)
KR (3) KR102177436B1 (el)
CN (2) CN106459204B (el)
AU (1) AU2015250760C1 (el)
BR (1) BR112016024575B1 (el)
CA (1) CA2946795C (el)
CY (1) CY1123743T1 (el)
DK (1) DK3134438T3 (el)
ES (1) ES2841249T3 (el)
HR (1) HRP20202047T1 (el)
HU (1) HUE052223T2 (el)
IL (2) IL248357B (el)
LT (1) LT3134438T (el)
MA (2) MA53069B1 (el)
MX (2) MX2016014000A (el)
MY (1) MY182444A (el)
NZ (1) NZ725423A (el)
PL (1) PL3134438T3 (el)
PT (1) PT3134438T (el)
RS (1) RS61379B1 (el)
RU (1) RU2698977C2 (el)
SA (1) SA516380131B1 (el)
SI (1) SI3134438T1 (el)
TN (1) TN2016000445A1 (el)
UA (1) UA122390C2 (el)
WO (1) WO2015162292A1 (el)
ZA (1) ZA201607095B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633448B2 (en) * 2014-04-25 2020-04-28 Pierre Fabre Medicament IGF-1R antibody-drug-conjugate and its use for the treatment of cancer
WO2017072196A1 (en) * 2015-10-26 2017-05-04 Pierre Fabre Medicament Composition for the treatment of igf-1r expressing cancer
EP3565842A1 (en) * 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
CA3106418A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
JP2022502431A (ja) 2018-09-27 2022-01-11 ピエール、ファーブル、メディカマン スルホマレイミドに基づくリンカーおよび対応する複合体
US20210380605A1 (en) * 2018-10-19 2021-12-09 Medimmune Limited Pyrrolobenzodiazepine conjugates
BR112022003635A2 (pt) 2019-09-04 2022-05-24 Pf Medicament Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso
EP4353220A1 (en) 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2661000B1 (fr) 1990-04-12 1992-08-07 Aerospatiale Machine d'essais d'eprouvettes en cisaillement.
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5561427A (en) 1994-12-30 1996-10-01 Psc Inc. Analog to digital converter with continuous conversion cycles and large input signal range
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
MX2008012146A (es) * 2006-03-28 2008-10-03 Biogen Idec Inc Anticuerpos anti-receptor 1 de factor de crecimiento tipo insulina (igf-1r) y uso de los mismos.
US20090068110A1 (en) 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
CN101687037B (zh) 2007-05-08 2013-07-10 健泰科生物技术公司 半胱氨酸改造的抗muc16抗体和抗体药物偶联物
US8937161B2 (en) 2007-10-19 2015-01-20 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
TW201138821A (en) * 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
ES2625818T3 (es) * 2011-04-19 2017-07-20 Merrimack Pharmaceuticals, Inc. Anticuerpos biespecíficos anti-IGF-1R y anti-ErbB3

Also Published As

Publication number Publication date
IL248357B (en) 2020-05-31
MA39378B2 (fr) 2021-02-26
CN106459204A (zh) 2017-02-22
RS61379B1 (sr) 2021-02-26
TN2016000445A1 (en) 2018-04-04
KR102357032B1 (ko) 2022-02-08
UA122390C2 (uk) 2020-11-10
JP2021073279A (ja) 2021-05-13
MX2016014000A (es) 2017-05-30
SA516380131B1 (ar) 2019-12-04
PT3134438T (pt) 2020-12-31
MA39378A1 (fr) 2018-05-31
US20170267766A1 (en) 2017-09-21
MA53069A1 (fr) 2021-10-29
CA2946795C (en) 2021-03-30
HRP20202047T1 (hr) 2021-02-19
AU2015250760C1 (en) 2023-11-16
CN112851808A (zh) 2021-05-28
JP7191134B2 (ja) 2022-12-16
DK3134438T3 (da) 2020-12-07
ZA201607095B (en) 2020-07-29
AU2015250760B2 (en) 2020-10-22
US11365259B2 (en) 2022-06-21
BR112016024575A2 (pt) 2017-10-10
IL274226A (en) 2020-06-30
NZ725423A (en) 2023-07-28
KR20220018620A (ko) 2022-02-15
PL3134438T3 (pl) 2021-04-06
KR20160145110A (ko) 2016-12-19
RU2016145277A (ru) 2018-05-28
AU2015250760A1 (en) 2016-11-03
CN106459204B (zh) 2021-02-02
EP3134438B1 (en) 2020-09-30
EP3783033A1 (en) 2021-02-24
KR102177436B1 (ko) 2020-11-12
RU2016145277A3 (el) 2018-12-13
WO2015162292A1 (en) 2015-10-29
MA53069B1 (fr) 2022-04-29
CA2946795A1 (en) 2015-10-29
US10202458B2 (en) 2019-02-12
US20190330353A1 (en) 2019-10-31
HUE052223T2 (hu) 2021-04-28
LT3134438T (lt) 2021-01-11
ES2841249T3 (es) 2021-07-07
IL248357A0 (en) 2016-11-30
JP6835591B2 (ja) 2021-02-24
MY182444A (en) 2021-01-25
SI3134438T1 (sl) 2021-04-30
KR20200128210A (ko) 2020-11-11
BR112016024575B1 (pt) 2024-02-27
RU2698977C2 (ru) 2019-09-02
MX2021002144A (es) 2021-03-09
EP3134438A1 (en) 2017-03-01
JP2017513898A (ja) 2017-06-01

Similar Documents

Publication Publication Date Title
CY1123743T1 (el) Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου
CY1124435T1 (el) Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α
CY1124252T1 (el) Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου
CY1122005T1 (el) Ανθρωπινα αντισωματα κατα toy pd-l1
CY1124747T1 (el) Ανθρωπινα αντισωματα σε pd-1
CY1122389T1 (el) Αντισωματα εναντι διεγειρομενου με γλυκοκορτικοειδες υποδοχεα παραγοντα νεκρωσης ογκου (gitr) και χρησεις αυτων
CY1124944T1 (el) Βελτιστοποιημενα αμφιειδικα αντισωματα αντι-cd3 και χρησεις αυτων
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
CY1126115T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CY1125440T1 (el) Αντι-τιμ-3 αντισωματα και συνθεσεις
CY1123884T1 (el) Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων
CY1124408T1 (el) ΣΤΟΧΕΥΜΕΝΗ ΑΝΑΣΤΟΛΗ TGFβ
CY1124384T1 (el) Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3
CY1120471T1 (el) Αντισωματα κατα του cd70
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
CY1123635T1 (el) Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του καρκινου των ωοθηκων και αλλων καρκινων
CL2019002144A1 (es) Conjugados de fármacos y anticuerpos anti–ccr7.
CU20160101A7 (es) Inmunoglobulina con fab en tándem
GT201700102A (es) Conjugados de anticuerpo-fármaco
MX2017012352A (es) Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
BR112016029372A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico isolado, vetor, métodos para produzir um anticorpo isolado ou fragmento de ligação de antígeno do mesmo, para preparar um conjugado e para aliviar um sintoma de um câncer, conjugado, e, uso de um conjugado.
MY174259A (en) Antigen binding protein and its use as addressing product for the treatment of cancer
UA117364C2 (uk) Похідні аматоксину